Erik W Gustafson

US Patent:

7527929, May 5, 2009

Filed:

Jul 29, 2005

Appl. No.:

11/194072

Inventors:

Kevin J. McKernan - Marblehead MA, US
Erik Gustafson - Norwood MA, US
Adrianne D. Brand - Wenham MA, US

Assignee:

Agencourt Bioscience Corporation - Beverly MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method of isolating a target species (e. g. , target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e. g. , buffer) that selectively removes (e. g.

US Patent:

20090191566, Jul 30, 2009

Filed:

Mar 3, 2009

Appl. No.:

12/396586

Inventors:

Kevin J. McKernan - Marblehead MA, US
Erik Gustafson - Norwood MA, US
Adrianne D. Brand - Wenham MA, US

Assignee:

AGENCOURT BIOSCIENCE CORPORATION - Beverly MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method of isolating a target species (e.g., target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e.g., buffer) that selectively removes (e.g., elutes) either the nucleic acid from the first functional group or the target nucleic acid species from the second functional group of the solid phase carriers, thereby isolating a target nucleic acid species from a mixture comprising a plurality of nucleic acid species.

US Patent:

20170140096, May 18, 2017

Filed:

Nov 11, 2016

Appl. No.:

15/349868

Inventors:

- Brea CA, US
Zihua Wang - Newton MA, US
Antonio Arevalo Reyes - Middleton MA, US
Erik Alan Gustafson - Alpharetta GA, US
John Steven Riley - Miami FL, US

International Classification:

G06F 19/24
C12Q 1/68
G06F 19/18
G06F 19/12

Abstract:

A method for determining the presence of a biological entity. The method may include entering into a digital computer, at least a plurality of first input values associated with a first genetic element, a plurality of second input values associated with a second genetic element, and a plurality of third input values associated with a third genetic element associated with a plurality of samples. The method also includes determining a threshold value associated with the third genetic element, separating the samples using the threshold value into a first set of samples and a second set of samples, clustering the first set of samples in a feature space defined by the first genetic element and the second genetic element, defining a first boundary space using the first set of samples, and defining a second boundary space using the second set of samples.

US Patent:

20140336143, Nov 13, 2014

Filed:

Dec 4, 2013

Appl. No.:

14/096166

Inventors:

- Foster City CA, US
- Boston MA, US
- Atlanta GA, US
Erik Gustafson - Norwood MA, US

Assignee:

GILEAD PHARMASSET LLC - Foster City CA
BETH ISRAEL DEACONESS MEDICAL CENTER - Boston MA
EMORY UNIVERSITY - Atlanta GA

International Classification:

C07H 19/06
C07D 409/04
C07D 405/04
C07D 239/54

US Classification:

514 50, 514274

Abstract:

A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.